CD274 and neoplasm: Established (PD-L1 expression) and promising (i.e., tumor mutational burden, circulating tumor DNA, imaging-based) biomarkers for ICI treatment in advanced NSCLC are available, but data specifically for sOMD NSCLC are limited.18